Global Urinary Tract Infection Testing Market to Generate $1,027.4 Million by 2031, Owing to Rise in Prevalence of Urinary Tract Infections Across the Globe

Urinary tract infection, in the simplest terms, is infection in the urinary system. The urinary system mainly comprises of kidneys, bladder, urethra, and ureters. There are several types of urinary tract infections, depending on the part or organ of the urinary system which is affected. Urinary tract infections generally start from the lower side, i.e., from the bladder and is treatable. However, serious complications can arise if the infection goes unchecked and spreads to the kidneys. Medical studies have found that the incidence of urinary tract infections is higher in women as compared to men.

Forecast Analysis of the Urinary Tract Infection Testing Market

In the recent years, there has been an increase in the prevalence of urinary tract infections across the globe. This growing prevalence is expected to be the primary growth driver of the urinary tract infection testing market in the 2022–2031 timeframe. Along with this, an overall increase in the R&D activities related to urinary tract infection testing kits is expected to push the urinary tract infection testing market further. Also, increase in usage of at-home sample collection kits and self-testing kits for urinary tract infection testing is predicted to offer numerous investment and growth opportunities to the market in the analysis timeframe. However, wrong results associated with urinary tract infection testing, may restrain the growth of the market in the forecast period.

Regionally, the urinary tract infection testing market in the North America region is expected to be the most dominant by 2031. Increase in the incidence of urinary tract infections and growing healthcare expenditure are expected to become the two main growth drivers of the market in this region during the forecast period.

According to the report published by Research Dive, the global urinary tract infection testing market is expected to gather a revenue of $1,027.4 million by 2031 and grow at 6.2% CAGR in the 2022–2031 timeframe. Some prominent market players include F. Hoffmann-La Roche Ltd, Sysmex Corporation, Quidel, Stryker, Cardinal Health, Bio-Rad Laboratories, Inc, Abbott, Danaher, ACON Labs, Siemens, and many others.

Covid-19 Impact on the Urinary Tract Infection Testing Market

The outbreak of the Covid-19 pandemic has had a massive negative effect on almost all industries and businesses across the world. The urinary tract infection testing market faced a moderate impact of the pandemic. An overall shutdown of manufacturing industries caused a decline in the production of urinary tract infection testing kits. However, a rise in urinary tract infections was noted during the pandemic and was considered by many medical experts as one of the effects of the virus. This increase in the incidence of urinary tract infections caused a growth in the demand for testing kits, which helped the market register some growth amidst the pandemic.

Significant Market Developments

The significant companies operating in the industry are adopting numerous growth strategies & business tactics such as partnerships, collaborations, mergers & acquisitions, and launches to maintain a robust position in the overall market, thus helping the urinary tract infection testing market to flourish. For instance:

• In July 2020, Uqora, the urinary biotechnology company, announced that it was launching a series of urinary diagnostic products specifically designed to address urinary tract infection issues. This new product line is expected to help the company to increase its footprint in the market in the coming period.

• In August 2020, TestCard, a healthcare technology platform, announced that it was launching an at-home urinary tract infection testing kit in the UK. This noninvasive testing method is predicted to help patients to get an idea about the urinary tract infection issues they are facing and seek medical help accordingly. Also, the launch is predicted to boost the market share of the company in the near future.
   
• In September 2022, Pathnostics, a leading medical laboratory in California, announced that it was collaborating with DispatchHealth, an at-home medical care provider, in order to conduct research involving a study of 6,800 patients suspected of having urinary tract infections. This collaboration will help both the parties to pool their resources and expertise and conduct the study in a holistic manner.